{
    "clinical_study": {
        "@rank": "124319", 
        "acronym": "SEGAN", 
        "arm_group": [
            {
                "arm_group_label": "Erythromycin", 
                "arm_group_type": "Experimental", 
                "description": "50 mg/kg/day divided every 6 hours oral for 7 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Dextrose 5 Water (D5W) equal amount as experimental every 6 hours oral for 7 days"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the relationship of reflux and apnea and to determine whether the administration\n      of erythromycin improves the incidence of GER and GER-associated apnea, bradycardic and/or\n      desaturation events in a prospective randomized controlled trial."
        }, 
        "brief_title": "Study of Erythromycin in GER-Associated Apnea of the Newborn", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Gastroesophageal Reflux", 
            "Apnea", 
            "Bradycardia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Apnea", 
                "Gastroesophageal Reflux", 
                "Bradycardia"
            ]
        }, 
        "detailed_description": {
            "textblock": "A randomized placebo-controlled trial to determine whether erythromycin, a drug known to\n      enhance gut motility, will improve the incidence of GER and GER-associated apnea,\n      bradycardiac and/or hypoxic events. The investigators have two aims: 1) to examine the\n      relationship between GER and apnea, bradycardia, and/or desaturation (ABD) events by\n      simultaneously employing a unique computer algorithm developed at the University of Virginia\n      to measure ABD events and an Multi-channel Intra-luminal Impedance (MII) pH monitoring to\n      measure GER episodes. 2)  In a randomized placebo-controlled trial, the investigators will\n      study whether erythromycin decreases GER and GER-associated apnea, bradycardia and/or\n      hypoxia in premature infants."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:Infants admitted to neonatal intensive care unit who are <37 weeks at\n        birth and >14 days of age, non-intubated, on full feeds for 3 days with one of the\n        following:\n\n          -  Any apnea, bradycardia, or desaturation (ABD) event, or\n\n          -  Documented symptoms of reflux\n\n        Exclusion Criteria:\n\n          -  major central nervous system, gastrointestinal, or complex cardiac anomalies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01825473", 
            "org_study_id": "16220"
        }, 
        "intervention": [
            {
                "arm_group_label": "Erythromycin", 
                "intervention_name": "Erythromycin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Erythromycin", 
                    "Placebo"
                ], 
                "intervention_name": "Multi-channel intra-luminal impedance (MII) pH monitoring", 
                "intervention_type": "Device", 
                "other_name": "Sandhill 6.5 French, product# ZINBS45E"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo (D5W)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Erythromycin stearate", 
                "Erythromycin", 
                "Erythromycin Estolate", 
                "Erythromycin Ethylsuccinate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "neonate", 
            "apnea", 
            "preterm", 
            "reflux", 
            "gastroesophageal reflux", 
            "impedance", 
            "erythromycin", 
            "desaturation", 
            "bradycardia", 
            "hypoxia"
        ], 
        "lastchanged_date": "April 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Charlottesville", 
                    "country": "United States", 
                    "state": "Virginia", 
                    "zip": "22903"
                }, 
                "name": "University of Virginia Children's Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Fara Davalian, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "David A Kaufman, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of Erythromycin in GER-Associated Apnea of the Newborn", 
        "overall_contact": {
            "email": "Fara.Davalian@virginia.edu", 
            "last_name": "Fara Davalian, MD", 
            "phone": "434-924-5428"
        }, 
        "overall_official": {
            "affiliation": "University of Virginia", 
            "last_name": "Fara Davalian, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Reflux Impedance events (both acidic and non-acidic) as recorded by Multichannel Intraluminal (MII) pH Impedance", 
            "safety_issue": "No", 
            "time_frame": "during day 6 to 7 of study treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01825473"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Virginia", 
            "investigator_full_name": "Faranek Davalian, MD", 
            "investigator_title": "Neonatology Fellow", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of apnea, bradycardia, and/or desaturation events (ABD) per computer algorithm developed at University of Virginia", 
                "measure": "ABD events per Physiologic Monitoring Database", 
                "safety_issue": "No", 
                "time_frame": "during the entire 7 days of treatment"
            }, 
            {
                "description": "Number of apnea, bradycardia, and/or desaturations (ABD) recorded by bedside nurse", 
                "measure": "ABD events recorded by nursing", 
                "safety_issue": "No", 
                "time_frame": "during the entire 7 days of treatment"
            }
        ], 
        "source": "University of Virginia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Virginia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}